MedinCell
↗Montpellier, France
MedinCell is a French biopharmaceutical company founded in 2003 and headquartered in Montpellier (Jacou), France. The company is a leader in long-acting injectable (LAI) therapeutics, pioneering its proprietary BEPO® technology platform—a biodegradable polymer-based delivery system that controls therapeutic drug release for extended periods (days, weeks, or months) from a small subcutaneous depot injection. MedinCell develops treatments across psychiatry, pain management, contraception, and infectious disease prevention, with applications addressing major global health needs. The company went public on Euronext Paris in 2007 and is now an emerging biopharmaceutical success story with strong commercial momentum from its first FDA-approved product.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:-
Industry:Biotechnology|Pharmaceuticals
Sub-Industry:Long-acting Injectable Therapeutics
SIZE & FINANCIALS
Employees:101-200
Revenue:$25.4M-$27.4M
Founded:2003
Ownership:public
Status:operating
FUNDING
Stage:Commercial/Post-IPO
Total Raised:$42.9M
Investors:Adage Capital Partners, Invus, Polar Capital LP, Wellington Management, Mirova, Syquant Capital, SITAM Belgique (Dassault Group), European Investment Bank, Unitaid, Gates Foundation
STOCK
Exchange:Euronext Paris
Ticker:MEDCL.PA
Market Cap:$783M
PIPELINE
Stage:Commercial|Phase 3|Preclinical
Lead Drug Stage:Commercial (FDA approved)
Modalities:Long-acting injectable, Polymer-based depot, Biodegradable copolymer, Bioresorbable formulations
Active Trials:3
Trial Phases:Phase 3: 1
FDA Approvals:2
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:CM Biomaterials JV (with Corbion, Netherlands)
Key Partnerships:Teva Pharmaceuticals, AbbVie, Corbion, Bill & Melinda Gates Foundation, Medicines Patent Pool
COMPETITION
Position:Challenger|Emerging Leader
Competitors:Johnson & Johnson (Invega Sustenna - paliperidone palmitate), Janssen Pharmaceuticals, Eli Lilly (Lybalvi), Otsuka Pharmaceutical, Lundbeck, Alkermes (Vivitrol, Aristada)
LEADERSHIP
Key Executives:
Christophe Douat - CEO & Chairman of Executive Board
Stéphane Postic - Chief Financial Officer
Richard Malamut - Chief Medical Officer
Philippe Guy - Chairman of the Board
Scientific Founders:Christophe Douat
Board Members:Philippe Guy, Dr. Sharon Mates, Dr. Charles Kunsch, Dr. Pascal Touchon
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with MedinCell. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.